Boston Scientific Reports the US FDA’s Expanded Approval of INGEVITY+ Pacing Leads for Conduction System Pacing
Shots:
- The US FDA has agreed to expand the indication of current-generation INGEVITY+ Pacing Leads to conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single or dual-chamber pacemaker
- The approval was based on results from INSIGHT-LBBA trial, involving 400 subjects, that examined INGEVITY+ pacing leads that had previously been implanted in the LBBA for anti-bradycardia pacing. It was supplemented by bench testing & LATITUDE Programming System data
- The INGEVITY+ Pacing Lead is assisted by a stylet, facilitating the device's positioning into the required location within the heart plus enables continuous pacing and impedance monitoring
Ref: Boston Scientific | Image: Boston Scientific
Related News:- Boston Scientific Receives CE Mark for its ACURATE Prime Aortic Valve System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
